Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Yes, some medications can lighten stool color: aluminum hydroxide antacids taken in large amounts may produce pale or clay-colored stool directly, while antibiotics and certain other drugs can trigger cholestasis or drug-induced liver injury that reduces bile flow and turns stool pale, gray, or putty-like. Barium used in imaging tests can have the same effect for a day or two. However, clay-colored stool is also a hallmark of bile duct blockage from gallstones, hepatitis, pancreatic or liver disease, especially when paired with dark urine, yellowing eyes or skin, itching, fever, or belly pain, so medication is not always the explanation. There are several important distinctions between harmless and urgent causes, including how long the color change lasts and which symptoms accompany it, so see below to understand more before assuming a prescription is to blame.
Because stool color alone cannot separate a temporary medication side effect from a blocked bile duct that needs prompt care, the fastest way to sort out your situation is a free, instant, online symptom check that reviews your medications and symptoms together and points you toward the right next step.
Last reviewed for medical accuracy: 09/15/2025
Pale White Clay-Colored Poop: Can Antacids or Antibiotics Be the Cause?
Seeing pale, white, or clay-colored stool can be unsettling. Normally, bile from your liver and gallbladder gives stool its brownish color. When bile flow is reduced or blocked, stools can turn pale or clay-colored. Let’s look at why this happens, whether common medications like antacids or antibiotics can play a role, and when to seek medical care.
• Bile pigments (bilirubin) produced by your liver break down in the intestines and give stool its characteristic brown color.
• When bile secretion into the gut is disrupted, stool may appear pale, grayish, or clay-colored.
Most antacids relieve heartburn by neutralizing stomach acid. Common ingredients include:
• Aluminum hydroxide
• Magnesium hydroxide
• Calcium carbonate
These antacids generally do not affect bile production or flow and therefore rarely turn stool clay-colored. However:
• Aluminum-based antacids can cause constipation, which may make stool appear harder or drier—and in very constipated states, stool may look paler than usual.
• Bismuth subsalicylate (Pepto-Bismol) is sometimes grouped with antacids; it more often turns stool black, not pale.
Bottom line: Standard over-the-counter antacids seldom cause true clay-colored stool.
While antibiotics are critical for treating infections, some can affect the liver or bile flow:
• Cholestatic hepatitis
– A rare side effect of certain antibiotics (e.g., amoxicillin-clavulanate, erythromycin)
– Can slow or block bile secretion, potentially leading to pale stools
• Microbiome disruption
– Broad-spectrum antibiotics can temporarily alter gut flora, affecting stool consistency and sometimes color
• Clostridioides difficile overgrowth
– Leads to diarrhea—usually yellowish or greenish, not clay-colored
– More about texture and frequency than true pallor
Although antibiotic-related pale stool is uncommon, if you notice persistent clay-colored bowel movements after starting an antibiotic, it’s wise to investigate further.
Beyond antacids and antibiotics, several drug classes may impair bile flow or liver function:
• Cholestatic agents
– Certain anabolic steroids
– Oral contraceptives or hormone replacement therapy in sensitive individuals
• Drugs with known hepatotoxicity
– High-dose acetaminophen (Tylenol) overdose
– Some anti-seizure medications (e.g., valproate)
• Contrast agents
– Barium sulfate used in imaging can produce chalky, white-looking stools until the substance clears
Clay-colored stool can be a sign of serious underlying issues. Seek prompt medical evaluation if you experience:
• Persistent pale or white stools lasting more than 48 hours
• Yellowing of the skin or eyes (jaundice)
• Dark urine (tea-colored)
• Severe abdominal pain, especially in the upper right quadrant
• Unexplained weight loss, fever, or chills
• Itchy skin (pruritus) without rash
These symptoms may indicate biliary obstruction, hepatitis, or other significant liver and gallbladder disorders.
Even if clay-colored stool follows a new medication, do not assume it’s harmless. You should speak to a healthcare professional if:
• Stool color doesn’t return to normal after stopping the suspect drug for 48–72 hours
• You develop jaundice or itching
• You have intense abdominal pain or nausea/vomiting
• You experience weight loss, fever, or fatigue
Prompt evaluation—blood tests, ultrasound, or other imaging—can identify or rule out serious liver or biliary conditions.
If clay-colored stool persists or is accompanied by concerning signs, please speak to a doctor. A timely diagnosis can prevent complications and guide you to the right treatment.
(References)
* Basagiannis CS, Panagoulias GS, Tentolouris N, Basoukeas S, Sambaziotis D, Ladas SD. Whipple disease. South Med J. 2010 Apr;103(4):353-6. doi: 10.1097/SMJ.0b013e3181d3949c. PMID: 20224490.
* Crowe SE. Helicobacter pylori Infection. N Engl J Med. 2019 Mar 21;380(12):1158-1165. doi: 10.1056/NEJMcp1710945. PMID: 30893536.
* Asharaf A, Desai P, Sanati M. Emphysematous Gastritis. J Am Osteopath Assoc. 2019 Dec 1;119(12):848. doi: 10.7556/jaoa.2019.140. PMID: 31790130.
* Maier L, Goemans CV, Wirbel J, Kuhn M, Eberl C, Pruteanu M, Müller P, Garcia-Santamarina S, Cacace E, Zhang B, Gekeler C, Banerjee T, Anderson EE, Milanese A, Löber U, Forslund SK, Patil KR, Zimmermann M, Stecher B, Zeller G, Bork P, Typas A. Unravelling the collateral damage of antibiotics on gut bacteria. Nature. 2021 Nov;599(7883):120-124. doi: 10.1038/s41586-021-03986-2. Epub 2021 Oct 13. PMID: 34646011; PMCID: PMC7612847.
* Nguyen CL, Markey KA, Miltiadous O, Dai A, Waters N, Sadeghi K, Fei T, Shouval R, Taylor BP, Liao C, Slingerland JB, Slingerland AE, Clurman AG, Maloy MA, Bohannon L, Giardina PA, Brereton DG, Armijo GK, Fontana E, Gradissimo A, Gyurkocza B, Sung AD, Chao NJ, Devlin SM, Taur Y, Giralt SA, Perales MA, Xavier JB, Pamer EG, Peled JU, Gomes ALC, van den Brink MRM. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients. Cell. 2023 Jun 8;186(12):2705-2718.e17. doi: 10.1016/j.cell.2023.05.007. Epub 2023 Jun 8. PMID: 37295406; PMCID: PMC10390075.
* Fujimoto K, Hayashi T, Yamamoto M, Sato N, Shimohigoshi M, Miyaoka D, Yokota C, Watanabe M, Hisaki Y, Kamei Y, Yokoyama Y, Yabuno T, Hirose A, Nakamae M, Nakamae H, Uematsu M, Sato S, Yamaguchi K, Furukawa Y, Akeda Y, Hino M, Imoto S, Uematsu S. An enterococcal phage-derived enzyme suppresses graft-versus-host disease. Nature. 2024 Aug;632(8023):174-181. doi: 10.1038/s41586-024-07667-8. Epub 2024 Jul 10. PMID: 38987594; PMCID: PMC11291292.
* Thänert R, Schwartz DJ, Keen EC, Hall-Moore C, Wang B, Shaikh N, Ning J, Rouggly-Nickless LC, Thänert A, Ferreiro A, Fishbein SRS, Sullivan JE, Radmacher P, Escobedo M, Warner BB, Tarr PI, Dantas G. Clinical sequelae of gut microbiome development and disruption in hospitalized preterm infants. Cell Host Microbe. 2024 Oct 9;32(10):1822-1837.e5. doi: 10.1016/j.chom.2024.07.027. Epub 2024 Aug 27. PMID: 39197454; PMCID: PMC11466706.
* Urbonas T, Petrauskas D, Kiudelis V, Jonaitis L, Skieceviciene J, Gedgaudas R, Kiudeliene E, Valantiene I, Zykus R, Varkalaite G, Inciuraite R, Trapenske E, Kulokiene U, Jonaitis P, Ramonaite R, Velickiene J, Zvirbliene A, Morkunas E, Kuliaviene I, Sumskiene J, Adamonis K, Macas A, Kupcinskiene K, Lukosiene L, Janciauskas D, Poskiene L, Vitkauskiene A, Ianiro G, Gasbarrini A, Kiudelis G, Kupcinskas J. Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules. J Gastrointestin Liver Dis. 2025 Jun 28;34(2):199-204. doi: 10.15403/jgld-5990. Epub 2025 Jun 28. PMID: 40580532.
* Grießhammer A, de la Cuesta-Zuluaga J, Müller P, Gekeler C, Homolak J, Chang H, Schmitt K, Planker C, Schmidtchen V, Gallage S, Bohn E, Nguyen TH, Hetzer J, Heikenwälder M, Huang KC, Zahir T, Maier L. Non-antibiotics disrupt colonization resistance against enteropathogens. Nature. 2025 Aug;644(8076):497-505. doi: 10.1038/s41586-025-09217-2. Epub 2025 Jul 16. PMID: 40670795; PMCID: PMC12350171.
* Kelly CR, Feuerstadt P. Diagnosis and Management of Clostridioides difficile. Am J Gastroenterol. 2026 Mar 1;121(3):628-634. doi: 10.14309/ajg.0000000000003844. Epub 2025 Nov 17. PMID: 41247039.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.